載入中
ProKidney Corp. is a biotechnology firm currently in the clinical trial phase, specializing in the development of innovative cell-based treatments. Their flagship product is Renal Autologous Cell Therapy (RAC-T), a unique cellular admixture derived from a patient's own cells. RAC-T is undergoing significant clinical evaluation; it is concurrently in Phase III and Phase II trials for individuals with moderate to severe diabetic kidney disease. Furthermore, the company is conducting a Phase I clinical trial to assess RAC-T's potential for patients born with congenital anomalies affecting the kidneys and urinary tract. The company was established in 2015 and operates from its headquarters in Winston-Salem, North Carolina.
前收盤價
US$1.74
+US$0.08 · +4.82%
盤中時間採用ET。市場資料可能有所延遲。
ProKidney Corp. is a biotechnology firm currently in the clinical trial phase, specializing in the development of innovative cell-based treatments. Their flagship product is Renal Autologous Cell Therapy (RAC-T), a unique cellular admixture derived from a patient's own cells. RAC-T is undergoing significant clinical evaluation; it is concurrently in Phase III and Phase II trials for individuals with moderate to severe diabetic kidney disease. Furthermore, the company is conducting a Phase I clinical trial to assess RAC-T's potential for patients born with congenital anomalies affecting the kidneys and urinary tract. The company was established in 2015 and operates from its headquarters in Winston-Salem, North Carolina.
日內區間
目前US$1.74
52週區間
目前US$1.74
盤中時間採用ET。市場資料可能有所延遲。
GoAI 評分
賣出
估值
42
合理估值
情緒
52
多空交錯
風險
75
高風險
動能
31
動能減弱
完整 GoAI 研究
繼續查看更深入的依據、催化因素和風險。
ProKidney Corp. is a biotechnology firm currently in the clinical trial phase, specializing in the development of innovative cell-based treatments. Their flagship product is Renal Autologous Cell Therapy (RAC-T), a unique cellular admixture derived from a patient's own cells. RAC-T is undergoing significant clinical evaluation; it is concurrently in Phase III and Phase II trials for individuals with moderate to severe diabetic kidney disease. Furthermore, the company is conducting a Phase I clinical trial to assess RAC-T's potential for patients born with congenital anomalies affecting the kidneys and urinary tract. The company was established in 2015 and operates from its headquarters in Winston-Salem, North Carolina.
日內區間
目前US$1.74
52週區間
目前US$1.74
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 89.3萬 USD | 7.6萬 USD | — | — | — |
| 毛利 | 89.3萬 USD | 7.6萬 USD | — | — | — |
| 研究與開發 | 1.14億 USD | 1.28億 USD | 1.07億 USD | 8207萬 USD | 4625.5萬 USD |
| 銷售、一般及管理費用 | 5177.7萬 USD | 5608.4萬 USD | 4481.5萬 USD | 7093.7萬 USD | 885.5萬 USD |
| 營業費用 | 1.66億 USD | 1.84億 USD | 1.52億 USD | 1.53億 USD | 5511萬 USD |
| 利息收入 | 1381.3萬 USD | 1975.2萬 USD | 2208.3萬 USD | 598.3萬 USD | 2000 USD |
| 利息支出 | 4000 USD | 9000 USD | 1.2萬 USD | 21.5萬 USD | — |
| 折舊和攤銷 | 657.5萬 USD | 543.2萬 USD | 385.3萬 USD | 303.6萬 USD | 198.4萬 USD |
| 營業利益 | −1.65億 USD | −1.84億 USD | −1.52億 USD | −1.53億 USD | −5511萬 USD |
| 淨利 | −6898.6萬 USD | −6118.6萬 USD | −3546.8萬 USD | −1.08億 USD | −5514.6萬 USD |
公司資料更新於 2026年10月11日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$4.67
上漲空間 168.39%報告持有此股票曝險的交易所交易基金。
iShares Russell 2000 ETFIWM450.26萬0.01%787.4億 USD0.19%US$278.94+0.49%
Vanguard Extended Market ETFVXF241.29萬0.00%954億 USD0.05%US$235+0.80%
Schwab U.S. Small-Cap ETFSCHA139.61萬0.01%218.24億 USD0.03%US$32.79+0.40%
iShares Russell 2000 Growth ETFIWO112.7萬0.01%139.17億 USD0.24%US$356.78+0.94%
Simplify Propel Opportunities ETFSURI84.17萬1.11%7606.44萬 USD2.82%US$17.06-0.14%
Vanguard Russell 2000 ETFVTWO81.77萬0.00%180億 USD0.06%US$112.66+0.50%
iShares Micro-Cap ETFIWC56.69萬0.04%13.17億 USD0.60%US$183+0.11%
Virtus Biotech Clinical Trials ETFBBC32.12萬0.78%4099.65萬 USD0.65%US$44.1456+2.08%iShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFSchwab U.S. Small-Cap ETFSCHAiShares Russell 2000 Growth ETFIWOSimplify Propel Opportunities ETFSURIVanguard Russell 2000 ETFVTWOiShares Micro-Cap ETFIWCVirtus Biotech Clinical Trials ETFBBCAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
